Srinivas Rao

Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation

Major Goals For ATAI: $175M Secured In Term Loan Facility, Plus Q2 Earnings Report

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation

Atai Partners With Harvard's Massachusetts General Hospital For Psychedelics Research

Psyched: Compass Joins Nasdaq, Field Trip Goes Public, MindMed Begins Trials, ATAI Launches MDMA Subsidiary

Srinivas Rao Recent News

ATAI Launches Subsidiary To Develop MDMA Derivatives

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO Glenn Short.

Arketamine: A Fast-Acting Antidepressant Without Dissociative Effects?

The Keys To Understanding Psilocybin's Medical Value, Market Potential